Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Granules IndiaBOM:532482 -0.48%81 Gross Margin % is 65.34% as of Jun. 2026, which is 33% above its 10-year median of 49.24. GuruFocus rates BOM:532482 with a GF Score™ of 81/100 and a GF Value™ of ₹637.97 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 942 Drug Manufacturers companies, Granules India ranks better than 76.11% on this metric.
The historical rank and industry rank for Granules India's Gross Margin % or its related term are showing as below:
BOM:532482'
s Gross Margin % Range Over the Past 10 Years
Min: 42.48 Med: 49.24 Max: 65
Current: 65
During the past 13 years, the highestGross Margin % of Granules India was 65.00%. The lowest was 42.48%. And the median was 49.24%.
BOM:532482's Gross Margin % is ranked better than 76.11% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:532482: 65.00
Granules India had a gross margin of 65.34% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Granules India was 4.20% per year.
Granules India (BOM:532482) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Granules India had a gross margin of 65.34% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Granules India Gross Margin % Related Terms
Granules India Gross Margin % Historical Data
* Premium members only.
The historical data trend for Granules India's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Granules India's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Granules India Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Granules India's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Granules India's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Granules India (BOM:532482) has a Gross Margin % of 65.34% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Granules India and its competitors. This is 33% above median its historical median of 49.24. Over the past decade, Granules India's Gross Margin % has ranged from 42.48 to 65.00. According to the industry distribution chart, Granules India ranks #225 out of 942 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Granules India's Gross Margin % too high?
Granules India's current Gross Margin % of 65.34% is 33% above median its 10-year median of 49.24. Over the past 10 years, this metric has ranged from a low of 42.48 to a high of 65.00. The Drug Manufacturers industry median Gross Margin % is 48.54. Granules India's value of 65.34% is 34.6% above this industry median. Based on the distribution chart, Granules India ranks #225 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Granules India has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Granules India's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Granules India ranks #225 out of 942 companies for Gross Margin %. This places Granules India in the top 24% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Granules India's value of 65.34% is 34.6% above this benchmark. Historically, Granules India's own Gross Margin % has ranged from 42.48 to 65.00 over the past decade. While the company's 10-year median is 49.24 vs. the industry median of 48.54, Granules India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Granules India's current Gross Margin % of 65.34% is 34.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Granules India and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Granules India's current Gross Margin % is 65.34%, which is 33% above median its own 10-year median of 49.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Granules India stock overvalued right now?
Based on GuruFocus' analysis, Granules India (BOM:532482) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹637.97, compared to a current price of ₹841.65 — trading 31.9% above its estimated fair value. The current Gross Margin % is 65.34%, which is 33% above median its 10-year median of 49.24 and 34.6% above the Drug Manufacturers industry median of 48.54. Granules India's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Granules India (BOM:532482), the current Gross Margin % is 65.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Granules India (BOM:532482) Overvalued in 2026?
Based on GuruFocus' analysis, Granules India stock appears to be overvalued.
The current stock price of ₹841.65 is trading 31.9% above its estimated GF Value™ of ₹637.97.
GuruFocus considers Granules India to be Significantly Overvalued.
Key valuation signals for BOM:532482:
Gross Margin %: 65.34% (33% above median its 10-year median of 49.24)
GF Value™: ₹637.97 vs. price of ₹841.65 (31.9% above fair value)
Industry Position: 34.6% above the Drug Manufacturers median (#225 of 942)
No single metric tells the full story. See the BOM:532482 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World. The company generates a majority of its revenue from its business outside India.
81GF Score
Get the complete analysis for BOM:532482
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532482 has been successfully added to your 
